A University of California, San Francisco study exploring how psilocybin affects the aging brain now has its study drug in hand. Filament Health, the Vancouver-area psilocybin developer now owned by Ontario-based Rhelion Life Sciences, said on Nov. 17 that it has shipped PEX010, its standardized natural psilocybin drug candidate, to UCSF for a Phase 1 trial known as OAD1.
The trial focuses on a group that psychedelic research has largely left out: healthy older adults whose sense of well-being is below average. It will also examine whether early biological signs linked to Alzheimer's disease change how participants respond.
According to the trial's federal registry record, OAD1 is a randomized, triple-blind study that plans to enroll about 80 adults between 50 and 85 years old. Participants must score below average on a standard World Health Organization well-being questionnaire and show no cognitive impairment on a common memory screening test. The study began in June and is recruiting at UCSF's Sandler Neuroscience Building in San Francisco, with completion estimated for early 2030.
The design compares four groups. Two receive psilocybin at either a lower or a higher dose, and two receive dextromethorphan, a common cough-medicine ingredient, at a lower or higher dose. Each participant gets a single dose during a supervised visit that lasts at least eight hours, followed by about three months of in-person and remote follow-up.
The researchers' central question is whether psilocybin acutely increases the complexity of brain activity, measured by EEG, in older adults with low well-being, and whether the presence of Alzheimer's-related biomarkers changes that effect. They also plan to track a blood marker of inflammation, along with heart and body signals from wearable devices and brain structure and function from MRI scans.
The study is led by UCSF researchers Lorenzo Pasquini, PhD, and Jennifer Mitchell, PhD. Mitchell is the trial's sponsor-investigator, and the registry lists support from the Brain & Behavior Research Foundation. Filament said it is supplying the drug only and is not the sponsor or responsible for running the trial.
PEX010 is Filament Health's lead botanical psilocybin drug candidate, made by extracting and standardizing psilocybin from mushrooms rather than synthesizing it in a lab. The company says PEX010 now supports more than 80 academic and philanthropic research studies worldwide, and that it comes in several standardized strengths with consistent composition across study sites.
Rhelion completed its acquisition of Filament on April 30, 2026, bringing over PEX010 and a portfolio of 78 issued patents across 13 patent families. In the same announcement, Rhelion said Benjamin Lightburn stepped down as company president effective Nov. 15. He remains a director.
Most psilocybin trials so far have focused on depression, PTSD and addiction in younger and middle-aged adults. OAD1 is part of a smaller push to understand how psychedelics act in older brains, including in people who may be in the earliest, symptom-free stages of Alzheimer's disease. The trial is designed to measure safety, feasibility and brain mechanisms, not to show that psilocybin treats or prevents any condition.
The shipment also highlights San Francisco's role as a research hub for psychedelic science, alongside UCSF's other psilocybin studies. Psilocybin is not approved by the FDA for any use and remains a Schedule I controlled substance under federal law, so studies like OAD1 run under federal research permits with pharmaceutical-grade supply.